'People want vanilla ice cream': CEO Anne Wojcicki grapples with 23andMe's dual identity

Andrew Dunn

Senior Biopharma Correspondent

SAN FRANCISCO — 23andMe CEO Anne Wojcicki said she’s “open to all ideas” in addressing investor confusion and turning around a disappointing start to the genomic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'People want vanilla ice cream': CEO Anne Wojcicki grapples with 23andMe's dual identity

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Peo­ple want vanil­la ice cream': CEO Anne Wo­j­ci­c­ki grap­ples with 23and­Me's dual iden­ti­ty

Senior Biopharma Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'People want vanilla ice cream': CEO Anne Wojcicki grapples with 23andMe's dual identity